Оптимізація базально-болюсної інсулінотерапії цукрового діабету 2-го типу на підставі фармакоекономічного аналізу

А. С. Колбін

Повний текст:

PDF

Посилання


IDF (International Diabetes Federation). Diabetes Atlas 3rd Edition. — 2006. — Р. 5.

Stumvoll M., Goldstein B., van Haeften T. Type 2 diabetes: principles of pathogenesis and therapy // Lancet. — 2005. — V. 365. — P. 1333–1346. https://doi.org/10.1016/s0140-6736(05)61032-x

Roglic G., Unwin N., Bennett P. et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000 // Diabetes Care. — 2005. — V. 28. — P. 2130–2135. https://doi.org/10.2337/diacare.28.9.2130

Gray R., Yudkin J. Cardiovascular disease in diabetes mellitus / In: Textbook of Diabetes 2nd Edition, 1997. Blackwell Sciences.

Stration M., Adlet A., Neil H. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) // BMJ. — 2000. — V. 321. — P. 405–412. https://doi.org/10.1136/bmj.321.7258.405

Nathan D., Buse J., Davidson M. et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes // Diabetes Care. — 2006. — V. 29. — P. 1963–1972. https://doi.org/10.2337/dc06-9912

Larme A., Pugh J. Attitudes of primary care providers toward diabetes: barriers to guideline implementation // Diabetes Care. — 1998. — V. 21. — P. 1391–1396. https://doi.org/10.2337/diacare.21.9.1391

Rossetti P., Porcellati F., Fanelli C. et al. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus // Arch Physiol. Biochem. — 2008. — V. 114 (1). — P. 3–10. https://doi.org/10.1080/13813450801900777

Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro // Diabetes. — 2000. — V. 49. — P. 2142–2148. https://doi.org/10.2337/diabetes.49.12.2142

Luzio S., Beck P., Owens D. Comparison of the subcutaneous absorption of insulin glargine (Lantus®) and NPH insulin in patients with type 2 diabetes // Horm. Metab. Res. — 2003. — V. 35. — P. 434–438. https://doi.org/10.1055/s-2003-41625

McMahon G., Dluhy R. Intention to treat — initiating insulin and the 4-T Study // N. Engl. J. Med. — 2007. — V. 357 (17). — P. 1759–1761. https://doi.org/10.1056/nejme078196

Gredal C., Rosenfalck A., Dejgaard A., Hilsted J. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes // Diabetes Res. Clin. Pract. — 2008. — V. 80 (2). — P. 293–298. https://doi.org/10.1016/j.diabres.2007.12.023

Apidra, prescribing information. Aventis Pharmaceuticals Kansas City, MO, USA (2004).

Becker R., Frick A., Burger F. et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique // Exp. Clin. Endocrinol. Diabetes. — 2005. — V. 113 (5). — P. 292-297. https://doi.org/10.1055/s-2005-865637

Becker R., Frick A., Burger F. et al. Insulin Glulisine, a New Rapid-Acting Insulin Analogue, Displays a Rapid Time-Action Profile in Obese Non-Diabetic Subjects // Exp. Clin. Endocrinol. Diabetes. — 2005. — V. 113 (8). — P. 435–443. https://doi.org/10.1055/s-2005-865806

Nosek L., Becker R., Frick A. et al. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin (Abstract) // Diabetes. — 2004. — V. 53. — P. A139.

Milicevic Z., Raz I., Beattie S. et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia // Diabetes Care. — 2008. — V. 31 (Suppl. 2). — S155–S160. https://doi.org/10.2337/dc08-s240

Brown J., Pedula K., Bakst A. The progressive cost of complications in type 2 diabetes mellitus // Arch. Intern. Med. — 1999. — V. 159. — P. 1873–1880. https://doi.org/10.1001/archinte.159.16.1873

Palmer J., Goodall G., Nielsen S. et al. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study // Curr. Med. Res. Opin. — 2008. — V. 24 (5). — P. 1417–1428. https://doi.org/10.1185/030079908x297295

Valentine W., Goodall G., Aagren M. et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes // Adv. Ther. — 2008. — V. 25 (6). — P. 567–584. https://doi.org/10.1007/s12325-008-0069-z

Белоусов Д.Ю. Фармакоэкономика инсулина гларгина (Лантус) по результатам зарубежных контролируемых исследований // Клин. фармакол. тер. — 2008. — Т. 17 (2). — С. 84–88.

Колбин А.С. Фармакоэкономика инсулина глулизин: увеличиваются ли затраты на государственное возмещение при сахарном диабете? // Кач. клин. практика. — 2008. — No 2. С. 47–52.

Колбин А.С. Фармакоэкономические аспекты применения аналогов инсулина. // Сахарный диабет. — 2008. — No 3. — С. 59-62. https://doi.org/10.14341/2072-0351-5363

http://diabet.apteka.ru

Rosenstock J., Davies M., Home P. et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes // Diabetologia. — 2008. — V. 51 (3). — P. 408–416. https://doi.org/10.1007/s00125-007-0911-x

Del Prato S., Nicolucci A., Vespasiani G. Optimising basal plus insulin therapy in type 2 diabetes by telecare assistance for self-monitoring of blood glucose — the ELEONOR study / 44-th Annual Meeting of EASD. — Roma, 2008. — A-08–2874.

Lee F., Zhang Q., Mersey J. et al. Glycaemic control and costs with insulin glargine plus glulisine versus premix — a randomized, prospective, observational study / 44-th Annual Meeting of EASD. — Roma, 2008. — A-08–1003.

Lankisch M., Ferlinz K., Scherbaum W. Adding a single dose of insulin glulisin at breakfast or main meal to basal insulin and oral antidiabetic therapy; which patients of the OPAL study benefit most? / 44-th Annual Meeting of EASD. — Roma, 2008. — A-08–2050.

Raslova K., Bogoev M., Raz I. et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes // Diabetes Res. Clin. Pract. — 2004. — V. 66. — P. 193–201. https://doi.org/10.1016/j.diabres.2004.03.003

Haak T., Tiengo A., Draeger E. et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes // Diabetes Obesity Metabol. — 2005. — V. 7. — P. 56–64. https://doi.org/10.1111/j.1463-1326.2004.00373.x

Liebl A., Prager R., Binz K. et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial // Diabetes Obes. Metabol. — 2008. https://doi.org/10.1111/j.1463-1326.2008.00915.x


Пристатейна бібліографія ГОСТ






DOI: https://doi.org/10.24026/1818-1384.1(30).2010.96437



Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Клінічна ендокринологія та ендокринна хірургія.

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter